Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.42 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | HBB | P68871 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CRYAA | P02489 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL29257538 | 0.95 | LMNA (0.43) | ENPEPLMNAALDH1A1THRBTP53 | |
| SCHEMBL29257532 | 0.86 | ENPEP (0.47) | ENPEPLMNAALDH1A1THRBTP53 | |
| Lithium Ion SCHEMBL29257535 | 0.82 | ENPEP (0.42) | ENPEPLMNAALDH1A1THRBTP53 | |
| Glycerin SCHEMBL1712543 | 0.82 | TP53 (0.58) | ENPEPLMNAALDH1A1THRBTP53 | |
| Glycerin SCHEMBL1712541 | 0.82 | TP53 (0.58) | ENPEPLMNAALDH1A1THRBTP53 | |
| Glycerin SCHEMBL2637741 | 0.79 | LMNA (0.53) | ENPEPLMNAALDH1A1THRBTP53 | |
| SCHEMBL15754444 | 0.79 | ENPEP (0.42) | ENPEPLMNAALDH1A1TP53KDM4E | |
| SCHEMBL15420731 | 0.79 | ENPEP (0.42) | ENPEPLMNAALDH1A1TP53KDM4E | |
| SCHEMBL15754666 | 0.77 | ENPEP (0.41) | ENPEPLMNAALDH1A1TP53KDM4E | |
| SCHEMBL28554323 | 0.77 | ENPEP (0.48) | ENPEPLMNAALDH1A1TP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1425311-A4 | CYCLODEXTRIN SULFONATES, GUEST INCLUSION COMPLEXES, METHODS OF MAKING THE SAME AND RELATED MATERIALS | EASTMAN CHEM CO (US) | 2004-12-01 | — | — | EP | claimed |
| EP-1425311-A2 | CYCLODEXTRIN SULFONATES, GUEST INCLUSION COMPLEXES, METHODS OF MAKING THE SAME AND RELATED MATERIALS | EASTMAN CHEMICAL COMPANY (US) | 2004-06-09 | — | — | EP | claimed |
| US-20040054164-A1 | Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials | EASTMAN CHEMICAL COMPANY (US) | 2004-03-18 | — | — | US | claimed |
| US-20020128468-A1 | Cyclodextrin sulfonates, guest inclusion complexes methods of making the same and related materials | BUCHANAN CHARLES M (US) | 2002-09-12 | — | — | US | claimed |
| WO-2002055562-A2 | CYCLODEXTRIN SULFONATES, GUEST INCLUSION COMPLEXES, METHODS OF MAKING THE SAME AND RELATED MATERIALS | EASTMAN CHEM CO (US) | 2002-07-18 | — | — | WO | claimed |
| US-20240360097-A1 | Compound and Method for Preparing Same | LG CHEM, LTD. (KR) | 2024-10-31 | — | — | US | disclosed |
| US-20240300915-A1 | Method for Preparing Cyclic Sulfonic Acid Ester Derivative Compound | LG CHEM, LTD. (KR) | 2024-09-12 | — | — | US | disclosed |
| EP-4365169-A1 | COMPOUND AND PREPARATION METHOD THEREOF | LG Chem, Ltd. (KR) | 2024-05-08 | — | — | EP | disclosed |
| CN-117881666-A | Compounds and methods for their preparation | 株式会社LG化学 | 2024-04-12 | — | — | CN | disclosed |
| EP-4342887-A1 | METHOD FOR PREPARING CYCLIC SULFONIC ACID ESTER DERIVATIVE COMPOUND | LG Chem, Ltd. (KR) | 2024-03-27 | — | — | EP | disclosed |
| CN-117561243-A | Process for the preparation of cyclic sulfonate derivative compounds | 株式会社LG化学 | 2024-02-13 | — | — | CN | disclosed |
| US-20240014443-A1 | Non-Aqueous Electrolyte Solution Additive for Lithium Secondary Battery, and Non-Aqueous Electrolyte Solution for Lithium Secondary Battery and Lithium Secondary Battery Which Include the Same | LG CHEM, LTD. (KR) | 2024-01-11 | — | — | US | disclosed |
| WO-2022211425-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION ADDITIVE FOR LITHIUM SECONDARY BATTERY, AND NON-AQUEOUS ELECTROLYTIC SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY, EACH COMPRISING SAME | 주식회사 엘지화학 | 2022-10-06 | — | — | WO | disclosed |
| US-7189798-B2 | Composition containing mixture of dihydroxybutane sulfonates | EASTMAN CHEMICAL COMPANY (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1425311-A4 | CYCLODEXTRIN SULFONATES, GUEST INCLUSION COMPLEXES, METHODS OF MAKING THE SAME AND RELATED MATERIALS | EASTMAN CHEM CO (US) | 2004-12-01 | — | — | EP | disclosed |
| EP-1425311-A2 | CYCLODEXTRIN SULFONATES, GUEST INCLUSION COMPLEXES, METHODS OF MAKING THE SAME AND RELATED MATERIALS | EASTMAN CHEMICAL COMPANY (US) | 2004-06-09 | — | — | EP | disclosed |
| US-20040054164-A1 | Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials | EASTMAN CHEMICAL COMPANY (US) | 2004-03-18 | — | — | US | disclosed |
| US-6610671-B2 | Cyclodextrin derivatives for use in cosmetics, pharmacolog, cosmetic, or nutrients | EASTMAN CHEMICAL COMPANY | 2003-08-26 | — | — | US | disclosed |
| US-20020128468-A1 | Cyclodextrin sulfonates, guest inclusion complexes methods of making the same and related materials | BUCHANAN CHARLES M (US) | 2002-09-12 | — | — | US | disclosed |
| WO-2002055562-A2 | CYCLODEXTRIN SULFONATES, GUEST INCLUSION COMPLEXES, METHODS OF MAKING THE SAME AND RELATED MATERIALS | EASTMAN CHEM CO (US) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360097-A1 | Compound and Method for Preparing Same | STS, NOTUM, CYP21A2 | THRB 4735/4885ENPEP 2069/4885LMNA 2654/4885 |
| US-20240014443-A1 | Non-Aqueous Electrolyte Solution Additive for Lithium Secondary Battery, and Non-Aqueous Electrolyte Solution for Lithium Secondary Battery and Lithium Secondary Battery Which Include the Same | TST, LRRK2, LAGE3 | THRB 2914/4885ENPEP 4034/4885LMNA 3082/4885 |
| US-20240300915-A1 | Method for Preparing Cyclic Sulfonic Acid Ester Derivative Compound | STS, TMT1A, TST | THRB 678/4885ENPEP 4056/4885LMNA 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.